Common Stock, $1.00 par value
- Symbol
- Not supplied
- Exchange
- Not supplied
- Classification
- COMMON
Current Report · Items 2.02, 8.01, 9.01 · 8-K
Baxter International Inc.
BAXNYSEEQUITYCurrent
Results of Operations and Financial Condition · Other Events
Item 2.02 Results of Operations and Financial Condition. On April 30, 2026, Baxter International Inc. (the Company) issued an earnings press release for the period ended March 31, 2026. The press release, including attachments, is furnished as Exhibit 99.1 to this report.…
Company context
At Baxter, we are everywhere healthcare happens - and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 37,500 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.
Current securities
Recent company filings
- 10-Q filingOct 29, 2026
- Results of Operations and Financial Condition · Other EventsOct 29, 2026
- 4 filingSep 3, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureAug 19, 2026
- Entry into a Material Definitive Agreement · Other EventsAug 18, 2026
Registered securities in this filing
Baxter International Inc. · 8-K · Filed 2026-04-30
Common Stock, $1.00 par value
- Symbol
- BAX (NYSE)
- Exchange
- NYSE
- Classification
- COMMON
1.3% Global Notes due 2029
- Symbol
- BAX 29
- Exchange
- NYSE
- Classification
- DEBT
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On April 30, 2026, Baxter International Inc. (the Company) issued an earnings press release for the period ended March 31, 2026. The press release, including attachments, is furnished as Exhibit 99.1 to this report.
The information in this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
Effective April 29, 2026, the Company's Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on July 1, 2026, to stockholders of record as of May 29, 2026.
Filed exhibits (1)
EX-99.1 2 bax-20260331xex991.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2026 RESULTS • Sales from continuing operations of $2.7 billion increased 3% on a reported basis and declined 1% on an organic basis1,2 • U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.03); adjusted diluted EPS from continuing operations of $0.36 • Reiterates full-year 2026 financial outlook DEERFIELD, Ill., APRIL 30, 2026 - Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2026. “Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution,” said Andrew Hider, president and CEO. “Although more work remains to achieve our full potential, Baxter continues to take the decisive steps necessary to fulfill our commitment to delivering better and more consistent results for our shareholders. I want to thank our colleagues for their resilience, dedication and mission-driven focus to support the more than 350 million patients around…
Open exhibit ↗